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1. 
SCAFFOLD FOR TISSUE REGENERATION 
IN MAMMALS 
REFERENCE TO RELATED APPLICATION 
This is a continuation of U.S. Ser. No. 12/504,489 filed 
Jul. 16, 2009 and issued Jul. 9, 2013 as U.S. Pat. No. 
8,481,066. 
FIELD OF THE INVENTION 
This invention relates to a biocompatible scaffold for 
implantation into mammals to facilitate tissue repair, regen 
eration, and proliferation. 
BACKGROUND OF THE INVENTION 
Day et al. U.S. Pat. No. 6,709,744 describes bioactive 
materials for implantation which include borate-based glass 
or ceramic materials containing 
NaO 20 to 35 wt % 
CaO 20 to 35 wt % 
POs 0 to 10 wt % 
BO, 30 to 50 wt % 
A specific example is a glass containing about 22.9 wt % 
NaO, about 22.9 wt % CaO, about 5.6 wt % P.O.s, and 
about 48.6 wt % B.O. These materials contain a high CaO 
concentration to facilitate the formation of hydroxyapatite 
when exposed to phosphorus-containing fluids in vivo or 
prior to implantation. These materials are in the form of 
loose particulates which are loosely packed, for example in 
a glass capillary tube for release into a host. Liang et al., 
Bioactive Borate Glass Scaffold for Bone Tissue Engineer 
ing, J. Non-Crystalline Solids 354 (2008), p. 1690-96; and 
Yao et al., In Vitro Bioactive Characteristics of Borate 
Based Glasses with Controllable Degradation Behavior, J. 
Am. Cer. Soc. 90 (2007), p. 303-306 also disclose borate 
based glasses formulated with high CaO to facilitate such 
formation of hydroxyapatite. For example, the OB, 1B, 2B, 
and 3B glasses described by Yao et al. contain 0, 17.7, 35.4, 
and 53 wt.% borate. 
SUMMARY OF THE INVENTION 
Briefly, therefore, the invention is directed to a three 
dimensional scaffold with interconnected pores for repair of 
tissue comprising a scaffold body for structural Support of 
the tissue scaffold, where the scaffold body comprises scaf 
fold body components bonded to each other to define the 
scaffold body and provide a scaffold body compressive 
strength of greater than 0.4 MPa, wherein the scaffold body 
components are of a component material comprising about 
40 to about 90 wt % BO, and two or more other oxides 
from among those discussed hereinbelow, wherein the scaf 
fold body has a porosity between about 15 and about 90 vol 
%. 
Other objects and features of the invention are in part 
apparent and in part pointed out hereinafter. 
BRIEF DESCRIPTION OF THE FIGURES 
FIG. 1A is a photograph of glass fibers employed in 
preparing a scaffold of the invention. 
FIG. 1B is a photograph of a mold used in preparing a 
scaffold of the invention. 













FIG. 2 is a photograph of a cross section of a scaffold of 
the invention. 
FIGS. 3A, 3B, 4A, 4B, 4C, and 4D are SEM micrographs 
of cross sections of a scaffold of the invention. 
FIGS. 5, 6, 7, 8A, 8B, 8C, and 8D are optical micrographs 
of cross sections of a scaffold of the invention subjected to 
histological staining. 
FIGS. 9A, 9B, 9C, 9D, 10A, 10B, 10C, and 10D are 
optical micrographs of cross sections of a scaffold employ 
ing prior art scaffold materials Subjected to histological 
staining. 
FIG. 11 is an x-ray diffraction profile of a scaffold 
discussed in a below Example. 
FIGS. 12A, 12B, 12C, 12D, 12E, and 12F are photo 
graphs of Scaffolds according to an Example. 
FIGS. 13A, 13B, 13C, 13D, 13E, 13F, 14A, 14B, 14C, 
14D, 14E, and 14F are photographs of scaffolds of FIGS. 
12A, 12B, 12C, 12D, 12E, and 12F after implantation. 
DESCRIPTION OF PREFERRED 
EMBODIMENTS 
This is a continuation of U.S. Ser. No. 12/504,489 filed 
Jul. 16, 2009 and issued Jul. 9, 2013 as U.S. Pat. No. 
8.481,066, the entire disclosure of which is incorporated by 
reference. 
The tissue scaffold of the present invention in one aspect 
employs structural components in the form of one or more 
of fibers, hollow fibers, tubes, ribbons, solid spheres, hollow 
spheres, particles, and combinations thereof. The compo 
nents are formed from a component material which is 
borate-based and which is glass, crystalline, or a combina 
tion of glass and crystalline, and which may or may not 
contain CaO for facilitating the formation of hydroxyapatite 
or other calcium phosphate compounds. 
The structural scaffold body components are bonded to 
each other, typically by heating, to define the scaffold body 
and provide a scaffold body compressive strength of greater 
than 0.4 MPa. The desired compressive strength is selected 
so that the components are in no sense free flowing, and so 
that the scaffold body can be handled without disintegrating 
into the individual body components. The desired compres 
sive strength is also selected to provide the strength that is 
required to remain integral after implantation, whether for 
repair of a load-bearing body part or non-load-bearing part, 
or one Subject to impact or significant movement. In some 
preferred embodiments, the compressive strength of the 
scaffold body is at least about 5 MPa, while in other 
embodiments where greater rigidity is required, the com 
pressive strength is at least about 20 MPa, such as between 
about 20 and about 200 MPa. 
In a preferred embodiment the material contains the 
following, with all percentages herein being by weight, 
unless stated otherwise: 
B2O3 40 to 90 
Na2O O to 25 
Li2O O to 25 
KO O to 25 
Rb2O O to 25 
CaO O to 40 
MgO O to 25 
SO O to 40 
BaO O to SO 
Li2O + NaO + K2O + Rb2O O to SO 
cumulative 
US 9,561,250 B2 
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MgO + SrO + BaO + CaO O to SO 
cumulative 
POs O to 10 
SiO2 O to 18 
Al2O3 O to 3 
F O to 4 
transition metal elements O to 10 
cumulative. 
The concentrations of KO and MgO in certain of these 
embodiments are each from about 1 to about 25 wt %. In 
most embodiments, the one or more of LiO, NaO, K2O, 
and RbC) is present in a cumulative concentration between 
about 1 and about 50 wt % and the one or more of MgO, 
SrO, BaO, and CaO is present in a cumulative concentration 
between about 1 and about 50 wt %, 
In most embodiments the scaffold consists only or essen 
tially of components meeting these compositional require 
ments or other narrower descriptions herein. But generally 
speaking, for some embodiments other materials not meet 
ing these descriptions may be incorporated into the scaf 
folds. 
Exemplary scaffold component materials within this 
description contain, by weight 96: 
TABLE I 
Wt. 90 Composition of Borate Glasses 
B.O. Na2O K-O Li2O CaO BaO MgO POs 
A. 53 6 12 2O 5 4 
B 70.4 10.3 19.3 
C 63.8 19 17.2 
D 49.3 14.6 36.1 
E 78.5 11.5 10 
F 70 1O.O 1O.O 1O.O 
G 78.7 11.3 1O.O 
H 78.7 11.3 1O.O 
I 76 11 13 
J 59 8 33 
It can therefore be appreciated that the scaffolds include 
component materials containing 40 to 90 wt % BO or 50 
to 90 wt % BO, or even the narrower BO ranges 
described herein, in combination with 1 to 25 wt % NaO. 
1 to 25% K2O, 1 to 40 wt % CaO, 1 to 25 wt % MgO, and 
1 to 10 wt % POs. Or the component materials may contain 
40 to 90 wt % BO, 1 to 25 wt % LiO, and 1 to 40 wt % 
CaO. Or they may contain 40 to 90 wt % BO, 1 to 25 wt 
% Na2O, and 1 to 40 wt % CaO. Or they may contain 40 to 
90 wt % BO, 1 to 25 wt % NaO, and 1 to 40 wt % BaO. 
Or they may contain 40 to 90 wt % BO, 1 to 25 wt % LiO, 
and 1 to 25 wt % MgO. Or they may contain 40 to 90 wt % 
BO, 1 to 25 wt % LiO, and 1 to 40 wt % BaC). While the 
scaffold component materials herein are described as con 
taining various oxides by weight '%, those skilled in the art 
understand that in the final glass or glass/crystalline com 
position, the individual oxygen, barium, boronetc. elements 
are largely dissociated, and the specific oxides, e.g., B.O. 
are not separately identifiable or even necessarily separately 
present. Nonetheless, it is conventional in the art to refer to 
the final composition as containing a given "% of the indi 
vidual oxides, so that is done here. So from this perspective, 
the compositions herein are on an equivalent basis. 
The scaffold component materials of the invention are 
borate-based in that they contain between about 40 and 













90 wt % B.O. Borate glasses have several important 
advantages for biological use Such as their ease of prepara 
tion, ability to be made into glass particulates, microspheres 
or fibers at relatively low temperatures without crystalliza 
tion, and, particularly, their biocompatibility and high 
degree of bioactivity. The borate glasses disclosed herein, 
compared to silicate glasses, have significantly faster reac 
tion rates, lower melting temperatures, resistance to crystal 
lization, and in certain instances the absence of silica which 
only slowly degrades in the body. So while certain embodi 
ments employ up to about 18 wt % SiO, in many other 
preferred embodiments herein, the scaffolds are silicate-free, 
containing less than 0.1 wt % Silicate or even no silicate. 
Borate glasses form hollow fibers upon reaction in vivo, 
while silicate glasses do not; and they facilitate angiogenesis 
in vivo. The borate glasses described herein also release 
boron in-vivo as they react with the body fluids, and since 
boron has been reported to promote bone density, and to 
Support the biological function of Mg and Ca, which are 
components of natural bone, borate glasses can provide an 
added function in bone repair/regeneration. 
The self-bonded scaffolds of borate glass fibers, described 
in the examples and figures herein, reacted rapidly with body 
fluids such that they lose up to 60% of their initial weight 
and are completely impregnated with vascularized soft tis 
sue in less than 4 weeks. The higher in vivo reaction rate of 
the borate glasses, which can be approximated by calcula 
tion as in below Example 9, substantially decreases the time 
the artificial material is in the body, and can promote faster 
complete healing of the defect. In preliminary in vivo 
experiments, borate glass appears to produce a significantly 
milder immune response than commercial bioactive silicate 
glass compositions. 
There is one embodiment which has specific preference in 
certain applications and wherein the concentration of Ca 
(elemental or in CaO or other compounds) in the scaffold 
body component material is controlled to less than about 5 
wt %. Certain preferred embodiments strictly control the Ca 
concentration to less than about 0.5 wt %, such as to less 
than 0.2 wt %, and even to less than 0.1 wt %. The advantage 
in this embodiment to strictly controlling Ca concentration 
is the avoidance of the formation of apatite and related 
compounds upon exposure to physiological phosphorus 
containing fluids. Such apatite compounds include hydroxy 
apatite Cas (PO4)(OH), fluoroapatite Cas(PO).F. and 
amorphous calcium phosphate (ACP). In certain applica 
tions it is advantageous to avoid the formation of Ca-apatite 
compounds because they have a relatively lower radiopacity 
than do, for example, analogous Ba compounds. In certain 
situations it is advantageous to avoid Ca-apatite compounds 
in order to form compounds which degrade more rapidly, or 
perhaps even more slowly. It can also be advantageous to 
avoid Ca for purposes of controlling melt characteristics, 
Such as Viscosity, melting temperature, and/or crystallization 
tendency. 
The scaffold of the invention which is constructed from 
Ca-free material in one embodiment preferably contains 
between about 40 and about 90 wt % BO with the 
remainder being selected from alkali oxides and alkaline 
earth oxides, and other optional constituents listed below. 
For example, this scaffold material contains, by weight %: 
B2O3 40 to 90 
Na2O O to 25 
Li2O O to 25 
US 9,561,250 B2 
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KO O to 25 
Rb2O O to 25 
MgO O to 25 
SO O to 40 
BaO O to 25 
Li2O + NaO + K2O + Rb2O O to SO 
cumulative 
MgO + SrO + BaO O to SO 
cumulative 
POs O to 10 
SiO, O to 18 
Al2O3 O to 3 
F O to 4 
transition metal elements O to 10 
cumulative. 
Certain of these embodiments contain low levels of Ca, as 
described above; while others are substantially Ca-free and 
contain essentially no or less than 0.1 wt % Ca. 
In one preferred embodiment, the material contains 
between about 50 and about 80 wt % B.O.; between about 
5 and about 20 wt % alkali oxide component selected from 
the group consisting of LiO, NaO, K2O, Rb2O, and 
combinations thereof, and between about 5 and about 40% 
alkaline earth component selected from the group consisting 
of MgO, SrO. BaO, and combinations thereof. While POs, 
SiO, Al2O, F, and transition metal elements. Lanthanides 
are specifically and strictly excluded from certain preferred 
embodiments. In some embodiments the scaffold material 
consists essentially of between about 50 and about 80 wt % 
B.O.; between about 5 and about 20 wt % alkali oxide 
component selected from the group consisting of LiO, 
NaO, KO, Rb O, and combinations thereof; and between 
about 5 and about 40 wt % alkaline earth component 
selected from the group consisting of MgO, SrO, BaO, and 
combinations thereof. 
Exemplary borate-based scaffold component Ca-free 
materials contain, by weight 96: 
TABLE II 
Wt. 90 Composition of Ca-Free Borate Glasses 
B.O. NaO Li2O MgO BaO 
I 49.3 14.6 36.1 
II 78.7 11.3 10 
III 78.7 11.3 10 
IV 76 11 13 
V 59 8 33 
VI 45 7 48 
VII 70 10 10 10 
In certain embodiments of the invention, the scaffold 
component materials are selected to include at least two of 
the alkali oxides LiO, NaO, KO, and/or RbO in a 
cumulative concentration of between about 5 and about 25 
wt %, such as between about 8 and 20 wt %. It has been 
discovered to be advantageous to include two or more Such 
alkali compounds in order to reduce the tendency for crys 
tallization, which ultimately improves the workability and 
manufacturability of the glasses to make Scaffolds. Using 
more than one type of alkali (i.e., mixed alkali) can reduce 
the cost of a glass, modify its reaction rate with body fluids, 
and provide additional elements beneficial to bone growth 
and regeneration. 
A further feature of certain embodiments of the invention 
is that the cumulative concentration of the alkaline earth 













and combinations thereof is in the range of 1 to about 50 wt 
%, such as in the range of 1 to 30 wt %, or even about 8 to 
25 wt %. Certain of these embodiments contain two or more 
such alkaline earth oxides in a range of 1 to 45 wt % 
cumulatively, such as in the range of 5 to 25 wt %. 
These scaffold embodiments employing scaffold material 
with mixed alkali oxide contents contain BO, from about 
40 to about 90 wt %. Certain of these embodiments consist 
essentially of BO, from about 40 to about 90 wt %, mixed 
alkali oxides selected from the group consisting of LiO, 
NaO, K2O, and RbC), and one of MgO, SrO, BaO, or CaO. 
Other embodiments consist essentially of BOs from about 
40 to about 90 wt %, two or more alkali oxides selected from 
the group consisting of LiO, NaO, K2O, and RbC), and 
two or more alkaline earth oxides from the group consisting 
of MgO, SrO. BaO, and CaO. For example, composition A 
in Table I consists essentially of BOs from about 40 to about 
90 wt %, two or more mixed alkali oxides selected from the 
group consisting of LiO, Na2O, K2O, and RbC) in a 
cumulative wt % between 5 and 25%, and two or more from 
among MgO, SrO. BaO, and CaO in a cumulative wt % 
between 8 and 25%. Other embodiments optionally include 
one or more of POs, SiO, Al2O, F, and transition metal 
elements. 
The invention includes scaffold embodiments employing 
scaffold material with an especially high BO composition, 
namely, from about 60 to about 90 wt %, preferably from 
about 60 to about 82 wt %, still more preferably from about 
70 to about 80 wt %. These embodiments employ an alkali 
oxide selected from the group consisting of LiO, NaO. 
KO, Rb2O, and combinations thereof cumulatively from 
about 1 to about 50 wt %, such as from about 5 to about 25 
wt %, and even from about 8 to about 20 wt %; and even 
optionally two or more Such oxides cumulatively in this 
range. They also optionally employ alkaline earth oxides 
from group consisting of MgO, SrO. BaO, CaO, and com 
binations thereof in the range of about 1 to about 50 wt %, 
such as in the range of 1 to 30 wt %, or even about 8 to 25 
wt %, and even two or more such oxides cumulatively in this 
range. Certain of these embodiments consist essentially of 
these components. Such as compositions II, III, IV, and VII 
in Table II; while other embodiments optionally include one 
or more of POs, SiO, Al-O. F. and transition metal 
elements. 
In the foregoing described mixed-alkali and high-borate 
embodiments, the Ca concentration may be strictly con 
trolled to less than about 5 wt %, including to less than 0.5 
wt %, such as to less than 0.2 wt % or less than 0.1 wt % to 
avoid the formation of Ca compounds. Alternatively, there 
are embodiments containing two or more alkali oxides 
which also contain CaO in an amount up to about 40 wt % 
to facilitate the formation of hydroxyapatite, other calcium 
phosphate compounds, or amorphous calcium phosphate. 
Another specific embodiment of the invention contains 
one or more elements selected from the group consisting of 
Zn, Cu, Fe, Mn, Si, F, Sr., Ni, Mo, and Se, in an amount 
between about 0.01 and 10 wt % per element and cumula 
tively less than 25 wt %. These are provided to the glass in 
the form of oxides or other compounds. These various 
optional elemental additions provide specific functions and 
advantages for specific applications. One or more of these 
elements within these ranges may also optionally be 
included in the previously described embodiments, i.e., the 
embodiment in which the cumulative concentration of the 
various alkali oxides from the group consisting of Li2O, 
NaO, K2O, Rb2O, and combinations thereof is maintained 
in the range of about 0 to about 30 wt %, and the embodi 
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ment in which the Ca concentration is strictly controlled to 
less than about 0.2 wt %, such as to less than 0.1 wt %. The 
trace elements may be incorporated as oxides into the 
scaffold materials. 
Nickel increases endothelial cell motility, which is an 
important step to angiogenesis. Cell motility is the migration 
of cells due to a stimulant, in this case the presence of the 
trace element Ni. 
Selenium functions as an antioxidant that is capable of 
protecting the body against oxidative stress associated with 
the natural immune response of creating excess reactive 
oxygen species to kill and destroy microbial pathogens and 
viruses. Essentially, the selenium is keeping the reactive 
oxygen species in check so that there is no negative response 
to the body cells and tissues. Animals with deficiencies in 
Selenium have shown impaired immune responses that 
resulted in phagocytic neutrophils and macrophages unable 
to combat antigens. Selenium Supplementation in animal 
models has been shown to increase several immune func 
tions, including, but not limited to; neutrophil migration, 
T-cell proliferation and function, cytotoxic T-cell activity, 
T-cell response, lymphokine-activated killer cell activity, 
and vaccine-induced immunity to malaria and polio. Most of 
these immune functions are natural to the wound healing 
process and increasing or promoting these cellular activities 
would promote wound healing. Therefore incorporating Se 
in the components of the invention promotes and stimulates 
natural biological immune responses required for soft tissue 
healing and regeneration. 
Zinc is a cofactor required for the formation of alkaline 
phosphatase, an enzyme found in bone tissue. The greatest 
amount of Zn in bone is located in the layer of osteoid prior 
to calcification. Zinc is a cofactor with Mg, therefore both 
must be present to gain the benefits of either. Zinc has been 
found to incorporate into hydroxyapatite, and when F is also 
present, the Zn and Zn-F complex may improve the 
crystallinity of the apatite. 
Copper, when deficient, inhibits bone growth and 
increases the changes associated with osteoporosis. Copper 
does not become incorporated into the HA, but is used by the 
osteoblast and osteoclast cells. When there is a deficiency, 
both osteoblast (bone formers) and osteoclast (bone resorb 
ers) decrease in activity. Osteoporosis is triggered by the 
greater relative reduction of osteoblast compared to the 
osteoclast. Copper has also been shown to have an effect on 
endothelial cell migration which can be useful for blood 
vessel formation and has potential importance for both hard 
and Soft tissue regeneration. The Source of Cu to the glass 
may be a copper oxide such as CuO or CuO or other copper 
compounds such as copper nitrate or copper Sulfate, for 
example. In one embodiment the copper compound is incor 
porated into the glass in a concentration of between about 
0.05 and about 5 wt %, such as between about 0.1 and about 
2.5 wt %. There are preferred embodiments employing from 
about 1 wt % to about 2 wt % copper compound, such as 
from about 1 wt % to about 2 wt % CuO. 
Iron acts as a signal for the enzymes that produce colla 
gen. Removal or absence of Fe will basically turn off the 
enzymes. 
Manganese acts as a cofactor for glycosyltransferases, 
which is the transfer of Sugar from a nucleotide-diphosphate 
Sugar to an acceptor molecule. Manganese is essential for 
several formation stages of glycosaminoglycan chondroitin 
Sulphate. Chondroitin Sulphate is a major constituent in 
connective tissues such as blood vessels, bone, and cartilage. 
Silicon is essential for normal bone matrix formation and 














conditions of depressed growth, abnormalities associated 
with the skull, long bone, and overall bone architecture. 
Silicon in bone is primarily located in osteoblast mitochon 
dria, the cells responsible for forming new connective tissue 
matrix material. 
Fluorine can affect hydroxyapatite crystallization by 
replacing a hydroxyl ion and improving the stability of the 
crystals. It is important to note that F must be incorporated 
into bone as it is forming, because it will not diffuse into 
formed bone. The skeletal system responds to F by increas 
ing the number of osteoblast (bone forming cells), hence 
forming more bone. The increase in osteocytes is due to the 
F increasing osteoprogenitor cell proliferation by increasing 
the activity of the bone cell mitogens (proteins that promote 
cell division). 
Strontium is believed to have metabolic effects on bone 
formation. Strontium has been shown in several animal 
models to reduce osteoclast (bone resorbing cells) activity 
without any toxic effect on the osteoclast cells. Increased 
replication of pre-osteoblastic cells has been seen with 
addition of Sr and led to an increase in bone matrix synthe 
sis. Strontium has been considered as a component for future 
treatment of osteoporosis. 
Accordingly, Some exemplary scaffolds of the invention 
such as in below Example 7 are constructed from scaffold 
body components such as fibers which contain, approxi 
mately, 40 to 90 wt % BO, 0.1 to 5% CuO, and NaO, 
KO, MgO, and POs. More specific examples contain or 
even consist essentially of 40 to 90 wt % BO, 0.1 to 5% 
CuO, 1 to 25 wt % NaO, 1 to 25 wt % KO, 1 to 25 wt % 
MgO, and 1 to 10 wt % POs. 
The scaffold component material may be glassy, glass 
ceramic, or ceramic in nature. However the glassy state is 
preferred in this invention because, generally speaking, 
glassy materials are stronger and more chemically homoge 
neous than their crystalline or partially crystalline counter 
parts of the same composition. It is therefore preferable that 
the scaffold body component material is Substantially glass 
in that less than about 5 wt %, more preferable less than 1 
wt %, of the component material is crystalline material. 
More particularly, it is preferable that there is less than 5 wt 
%, preferably less than 1 wt %, crystallization when the 
material is heated to 800 C at an average heating rate of 20 
C/min, held at that temperature for 10 minutes, then cooled 
to room temperature by exposure to STP conditions of room 
temperature and atmospheric pressure. More preferably, the 
glass will contain less than 5 wt % crystallization, even more 
preferably less than 1 wt % crystallization, after being 
heated to 575 C with a ramp rate of 20 C/min, and held at 
that temperature for 20 minutes, then cooled to room tem 
perature by exposure to STP conditions. 
The scaffold body components of the invention are in the 
form of solid fibers, hollow fibers, ribbons, solid spheres, 
hollow spheres, particles, and combinations thereof. In an 
especially preferred embodiment for many applications, the 
scaffold body components include fibers, and in certain Such 
embodiments the scaffold body consists essentially of com 
ponents which are fibers. The fibers have an aspect ratio of 
at least 2:1 length:transverse dimension (e.g., diameter), and 
more typically at least 5:1. Such as greater than 10:1. In 
certain embodiments of the invention, the scaffold body 
components are primarily one form, such as fibers, in 
combination with a minor constituent of a second form from 
the foregoing options, such as microspheres. 
There is also an option with this invention of employing 
distinct component compositions to strategically impart cer 
tain properties. For example, the scaffold body employs 10 
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from the above Tables I and II, and 10 to 90 wt % of 
components of a different composition from these Tables. Or 
even more than two Such types of components may be 
employed. That is, the scaffold may contain at least 10 wt % 
of the scaffold body components comprising a first compo 
nent material within the contemplated compositions and at 
least 10 wt % of scaffold body components comprising a 
second component material within the contemplated com 
positions, wherein the first and second component materials 
have compositions distinct from each other. This permits the 
selection of for example, faster reacting fibers in combina 
tion with slower reacting fibers; or the selection of Ca 
containing fibers with Ca-free fibers; or the selection of trace 
element-containing fibers with non-trace-element-contain 
ing fibers, to name a few combinations. One can therefore 
select standard composition components and combine them 
with non-standard composition components to effectively 
customize or dope the scaffold for the application presented, 
or for the host’s particular needs. Alternatively, hollow 
spheres containing a growth factor or drug for delivery to the 
host can be incorporated with other structural components, 
such as fibers. 
The scaffold is formed to have a porosity which is selected 
to provide fluid flow into the scaffold to facilitate uptake of 
bodily fluids, while maintaining sufficient strength for han 
dling and implantation. The porosity is between about 15 vol 
% and about 90 vol%. There are different levels of porosity, 
for example between about 15 and about 30 vol %, or 
between about 30 and about 60 vol%, or between about 60 
and about 90%, which are preferred for different applica 
tions. Porosity depends on or is controlled by many factors 
Such as fiber orientation, shape of particles or microspheres, 
and the thermal treatment (time/temperature) used to bond 
the elements together. Independent of this bulk porosity, 
interconnectivity is also important in the scaffolds of the 
invention. Because tissue repair is strongly influenced by 
flow of bodily fluids into the scaffold, it is preferred to have 
a high level of interconnectivity of pores within the scaffold, 
and a low level of closed pores. That is, it is important that 
most pores be connected to other pores, and that there is a 
director indirect path from most pores to the exterior surface 
of the scaffold. In certain embodiments, at least about 80 vol 
%, such as at least about 90%, of the pore volume of the 
scaffold is directly or indirectly through other pores acces 
sible from the scaffold exterior, and therefore accessible to 
bodily fluids. 
The method of making the scaffold component materials 
is not critical to the invention. By way of example, in 
preparing the scaffold component materials, individual ana 
lytical reagent grade components are weighed, mixed thor 
oughly, and melted in a platinum crucible for approximately 
one hour at 1050 C. The melt is then quenched, for example, 
on a steel or copper plate to form glass that can be ground 
into particulates of a desired size. The particulates can be 
spheroidized to form microspheres of a chosen diameter. 
The material of preferred composition when in the form of 
a melt can easily be formed into fibers. If fibers of the borate 
glass are made, they can either be pulled by hand directly 
from the melt or pulled through bushing by a rotating drum. 
The components can be self bonded to form three dimen 
sional scaffolds by simply heating an assemblage of par 
ticulates in a furnace and allowing the fibers/particles/ 
spheres to soften and bond to each other. After the allotted 
time at temperature, the construct is removed from the 
furnace and cooled to room temperature. Many prior bio 














crystallization of the glass. Therefore the self-bonding abil 
ity of the borate glasses of the invention is a distinct 
advantage over other bioactive materials currently in use. 
EXAMPLE 1. 
A scaffold of the invention was formed from glass fibers 
shown in FIG. 1A, which were about 3 mm long on average 
and between about 100 and about 300 microns in diameter. 
The fiber composition was, by wt %, 53 B.O., 6 NaO, 12 
KO, 5 MgO, 20 CaO, and 4 POs. The fibers were placed 
in the scaffold mold (mullite tube) of FIG. 1B, which was 7 
mm in diameter, and enough fiber was placed in the mold 
(70 mg) to make a scaffold 2 mm in height. The mold with 
fibers randomly oriented therein was placed in a furnace, 
with an atmosphere of air and ambient pressure, and heated 
for 45 minutes at 575 C. The temperature ramp rate to 575 
was about 100 C/min. The scaffold was then removed from 
the furnace and the mold allowed to air cool at room 
temperature. The scaffold was then removed from the mold 
and is depicted in FIG. 1C. 
EXAMPLE 2 
A borate based glass fiber scaffold of the invention was 
prepared in the manner described in Example 1 and embed 
ded in epoxy. A cross section was formed and an optical 
photomicrograph was taken and is shown in FIG. 2. The 
lighter areas are the epoxy, while darker, rounded shapes are 
the glass fibers. They have irregular shapes due to the 
random orientation of the fibers in the scaffold. Substantial 
self bonding is evident where two or more rounded shapes joined. The high degree of interconnectivity of porosity is 
also evident from this figure. 
EXAMPLE 3 
A self-bonded borate glass scaffold of the type of 
Examples 1 and 2 was implanted Subcutaneously in the back 
of a rat. After four weeks, the scaffold was removed and 
examined by scanning electron microscopy (SEM). A micro 
graph was taken (FIGS. 3A and 3B) which revealed soft 
tissue Surrounding the fibers. This demonstrates uptake of 
physiological fluid into the scaffold and growth of soft tissue 
within the scaffold. A hollow core formed in many of the 
fibers, as shown, indicating reaction of the glass fibers with 
physiological fluids. This is in contrast to the solid nature of 
the fibers prior to implantation as shown in FIG. 2. FIGS. 
4A, 4B, 4C, and 4D are micrographs at Successively higher 
magnifications of one of the fibers from FIGS. 3A and 3B. 
The porous reaction layer visible in FIGS. 4C and 4D is 
evidence of hydroxyapatite formation. This is confirmed by 
the X-ray diffraction analysis of the scaffold shown in FIG. 
11, which reveals a pattern consistent with Cao(PO) 
(OH). 
EXAMPLE 4 
A cross section similar to that shown in FIGS. 3A and 3B 
having been removed from a rat after four weeks subcuta 
neous implantation was Subjected to histological staining 
(H&E), and is shown in FIG. 5. This demonstrates biological 
compatibility between the tissue and the scaffold, the glass 
reaction with the body fluids which formed hollow fibers of 
HA and or ACP, and the tissue infiltration throughout the 
scaffold and into the hollow voids of the reacted fibers. A 
further cross section was taken in a direction parallel to the 
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central longitudinal axis of a reacted fiber, and is shown in 
FIG. 6. The center of the photomicrograph shows substantial 
presence of red blood cells and soft tissue in the sectioned 
fiber. FIG. 7 is a further photomicrograph of a cross section 
taken in a direction perpendicular to the central axis of a 
fiber. Red blood cells, blood vessels, and soft tissue can be 
seen in the hollow core of the reacted glass fiber. 
EXAMPLE 5 
The immune response of the borate glass of the invention 
in comparison to prior art glasses was studied by H&E 
staining and examination of cross sections of respective 
scaffolds. The sections in FIGS. 8A, 8B, 8C, and 8D were 
taken of a scaffold of the invention after two weeks subcu 
taneous implantation in the back of a rat. These sections 
show healthy Soft tissue growing between and attached to 
the glass fibers. 
There are no giant cells visible close to the fibers. There 
are areas with good vascularization, which is important to 
the growth of new tissue. Stained sections of a prior art 
silicate-based bioactive glass known as 13-93 are shown in 
FIGS. 9A, 9B, 9C, and 9D, and almost all the fibers (e.g., F 
in 9B) have giant cells attached to and surrounding them. 
12 
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The compounds listed in the right hand column are 
reaction products after reacting particles of each glass in a 
0.25 molar solution of KHPO at 37 C for 108 to 130 hours. 
EXAMPLE 7 
Several borate-based glasses were prepared containing 
trace amounts of Cu, Sr., Zn, and Fe as oxides in various 
amounts according to the following concentrations: 
Trace Element Doped Borate Bioactive Glasses (wt % 
Glass 
The soft tissue penetrating the fibers appears healthy, but the 
giant cells Surrounding the fibers are indicative of a foreign 
body response. A similar response to the 13-93 glass fibers 
occurs for prior art 45S5 glass fibers, as shown in FIGS. 
10A, 10B, 10C and 10D. Nearly all the 45S5 fibers are 
Surrounded by giant cells indicative of a foreign body 
response. The results shown in FIGS. 8A, 8B, 8C, 8D, 9A, 
9B, 9C, 9D, 10A, 10B, 10C and 10D indicate that the 
material of invention has no significant immune response 
with Soft tissue, and can convert to hydroxyapatite at a much 
faster rate than the silicate based bioactive glasses. This 
illustrates that the scaffold of the invention, when placed in 
contact with tissues containing body fluids, forms a porous 
hydroxyapatite material with a hollow core, which can fill 
with biological material Such as hard and soft tissue (de 
pending on the Surrounding tissues), blood vessels, or pos 
sibly other tissues of the body. The histological assessment 
after implantation in Subcutaneous soft tissue sites showed a 
minimal immune response to the Surrounding and infiltrated 
Soft tissue. It also appears to produce a smaller foreign body 
response than silicate based bioactive glasses such as 45S5 
and 13-93. 
EXAMPLE 6 
In-vitro experiments were conducted to measure the reac 
tion rates and the reaction products of the following Ca-free 
borate-based glasses (compositions in weight 96): 
B.O. Na-O CaO K-O MgO POs CuO SrO ZnO FeO. 
S3.OO 6.OO 20.00 12.00 S.OO 4.OO 
S2.95 S.99 19.98 11.99 S.OO 4.OO 0.10 
52.89 S.99 19.96 11.98 4.99 3.99 0.2O 
52.79 5.98. 19.92 11.95 4.98 3.98 0.40 
52.47 S.94 19.8O 11.88 495 3.96 1.00 
S1.94 S.88 19.6O 11.76 4.90 3.92 2.00 
S1.73 S.86 19.52 11.71 4.88 3.90 O.40 2.00 
S120 S.80 19.32 11.59 4.83 3.86 0.40 2.OO 100 
SO.88 5.76 19.2O 1152 4.80 3.84 040 2.OO 100 0.40 







which are depicted in FIGS. 12A, 12B, 12C, 12D, 12E, and 
12F, respectively. These were implanted subcutaneously in 
the backs of rats, and examined for vascularization. FIGS. 
13A, 13B, 13C, 13D, 13E, and 13F show the extent of 
vascularization after two weeks, and FIGS. 14A, 14B, 14C, 
14D, 14E, and 14F after four weeks, for glasses 0 through 
5, respectively. The effect of increasing Cu content on 
increasing vascularization is evident. 
EXAMPLE 8 
A blended fiber scaffold was prepared from a 50:50 by 
weight mixture of fibers of two distinct compositions: 
Glass 
Fiber 
Content B.O. NaO CaO K-O MgO POs CuO 
50% 53.00 6.OO 2O.OO 12.OO SOO 4.OO 
50% 52.47 5.94 1980 11.88 495 3.96 1.OO 
EXAMPLE 9 
The dissolution of boric acid in vivo is calculated. With a 
53 wt % B.O. glass and an exemplary scaffold mass of 0.070 
g, the weight of BO is 0.0371 g. The BO dissolves into 
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the bodily fluids and is present as BO ions. For purpose of 
comparison to literature values, however, calculation here is 
made on the basis of HBO. The gravimetric factor of BO 
to HBO is 1.78, so the 0.0371 g of BO dissolves into 
0.066 g HBO, which corresponds to 1.07E moles 
HBO. It was assumed, based on in vivo observations, that 
it takes four weeks for a B.O. based scaffold of this size to 
completely react. This corresponds to 1.07E/28 
days=3.814E moles/day HBO, yield. Prior observations 
also show that roughly 0.05 g of new tissue weight grows 
into a scaffold of this size. Prior observations also show that 
roughly between about 0.1 (minimum) and about 0.4 (maxi 
mum) ml/min of blood flows through a scaffold per gram of 
tissue. First assuming the minimum flow, the HBO, yield is 
calculated to have a concentration of 5.29 mM: 1440 min/ 
day (0.1 ml/ming)(1 day) (0.05 g)=7.2 ml=0.0072 L. 
3.814E moles/day HBO/0.0072 L=5.29E mol/L=5.29 
mM HBO. Then assuming the maximum flow, the HBO 
yield is calculated to have a concentration of 1.32 mM: 1440 
min/day (0.4 ml/min/gram)=28.8 ml=0.0288 L. 3.814E 
moles/day HBO/0.0288 L=1.32E mol/L=1.32 mM 
HBO. Based on data available in “Action of Boron at the 
Molecular Level, Bio. Trace Ele. Res., 85, 2002, HBO, in 
this concentration may stimulate RNA uptake. Accordingly, 
in sharp contrast to silicate-based scaffolds, the scaffolds of 
the invention upon dissolution naturally yield a Substance 
which has been reported to function as a growth factor to 
enhance healing. 
In view of the above, it will be seen that the several 
objects of the invention are achieved and other advantageous 
results attained. 
When introducing elements of the present invention or the 
preferred embodiments(s) thereof, the articles “a”, “an', 
“the' and “said are intended to mean that there are one or 
more of the elements. The terms “comprising”, “including 
and “having” are intended to be inclusive and mean that 
there may be additional elements other than the listed 
elements. 
As various changes could be made in the above compo 
sitions and methods without departing from the scope of the 
invention, it is intended that all matter contained in the 
above description and shown in the accompanying drawings 
shall be interpreted as illustrative and not in a limiting sense. 
The invention claimed is: 
1. A three-dimensional scaffold with interconnected pores 
for repair of tissue comprising: 
a scaffold body for structural support of the tissue scaffold 
comprising: 
scaffold body components bonded to each other to define 
the scaffold body and provide a scaffold body com 
pressive strength of greater than 5 MPa, wherein the 
Scaffold body components are components in the form 
of fibers in combination with one or more components 
in the form of ribbons, solid spheres, hollow spheres, 
and particles, and the components are of a component 
material comprising, by approximate weight 96: 
B2O3 40 to 90 
Na2O O to 25 
Li2O O to 25 
KO O to 25 
Rb2O O to 25 
CaO O to 40 
MgO O to 25 
SO O to 40 
BaO O to SO 














SiO2 O to 18 
Al2O3 O to 3 
F O to 4 
transition metal elements O to 10 
cumulative 
wherein two or more of LiO, Na2O, K2O, and Rb-O are 
present in a cumulative concentration between about 1 
and about 50 wt %, 
wherein two or more of MgO, SrO, BaO, and CaO are 
present in a cumulative concentration between about 1 
and about 50 wt %, 
wherein the scaffold body has a porosity between about 15 
and about 90 vol%. 
2. The scaffold of claim 1 wherein the BO concentration 
is between about 50 and about 90 wt %. 
3. The scaffold of claim 1 wherein the BO, concentration 
is between about 60 and about 82 wt %. 
4. The scaffold of claim 1 wherein: 
the BO concentration is between 50 and 90 wt %; 
the component material comprises two or more oxides 
from among Li2O, NaO, KO, and RbC) in a cumu 
lative concentration between 5 and 25 wt % and two or 
more oxides from among MgO, SrO, BaO, and CaO in 
a cumulative concentration between 1 and 45 wt %; and 
less than 5 wt % of the component material is crystalline 
material. 
5. The scaffold of claim 1 wherein the scaffold body 
components contain MgO in a concentration is between 
about 1 and 25 wt %. 
6. The scaffold of claim 1 wherein the scaffold body 
components contain KO in a concentration is between 
about 1 and 25 wt % and MgO in a concentration is between 
about 1 and 25 wt %. 
7. The scaffold of claim 1 wherein the component material 
comprises two or more oxides from among LiO, NaO. 
KO, and RbC) in a cumulative concentration between 5 and 
25 wt %. 
8. The scaffold of claim 1 wherein the component material 
comprises two or more oxides from among LiO, NaO. 
KO, and RbC) in a cumulative concentration between 5 and 
25 wt % and two or more oxides from among MgO, SrO. 
BaO, and CaO in a cumulative concentration between 1 and 
45 wt %. 
9. The scaffold of claim 1 wherein the component material 
further comprises one or more elements selected from the 
group consisting of Zn, Cu, Fe, Mn, Si, Sr., Ni, Mo, and Se, 
in an amount between about 0.01 and 10 wt % per element 
and cumulatively less than 25 wt %. 
10. The scaffold of claim 1 wherein the component 
material further comprises between about 0.01 and 10 wt % 
Cu as copper oxide. 
11. A three-dimensional scaffold with interconnected 
pores for repair of tissue comprising: 
a scaffold body for structural support of the tissue scaffold 
comprising: 
scaffold body components bonded to each other to define 
the scaffold body and provide a scaffold body com 
pressive strength of greater than 0.4 MPa, wherein the 
Scaffold body components are of a component material 
comprising, by approximate weight 96: 
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B2O3 40 to 90 
NaO O to 25 
Li2O O to 25 
KO O to 25 
Rb2O O to 25 
CaO O to 40 
MgO O to 25 
SO O to 40 
BaO O to SO 
POs O to 10 
SiO2 O to 18 
Al2O3 O to 3 
F O to 4 
transition metal elements O to 10 
cumulative 
wherein two or more of LiO, NaO, K2O, and RbC) are 
present in a cumulative concentration between about 1 
and about 50 wt %, 0 
wherein two or more of MgO, SrO, BaO, and CaO are 
present in a cumulative concentration between about 1 
and about 50 wt %, 
wherein the scaffold body has a porosity between about 15 
and about 90 vol%, and 
wherein at least 10 wt % of the scaffold body components 
have a first composition and at least 10 wt % of the 
Scaffold body components have a second composition, 
wherein the first and second compositions are distinct 
from each other. 
12. The scaffold of claim 1 wherein less than 5 wt % of 
the component material is crystalline material. 
13. The scaffold of claim 1 wherein the component 
material, upon exposure to natural or simulated physiologi 
cal phosphorus-containing fluids, does not react to form a 






14. The scaffold of claim 1 wherein the body components 
comprise the glass fibers and the particles. 
15. The scaffold of claim 1 wherein the scaffold body 
consists essentially of the glass fibers and the one or more 
components in the form of ribbons, solid spheres, hollow 
spheres, and particles. 
16. The scaffold of claim 1 wherein the scaffold body 
components consist essentially of 40 to 90 wt % BO, 1 to 
25 wt % NaO, 1 to 25% K2O, 1 to 40 wt % CaO, 1 to 25 
wt % MgO, and 1 to 10 wt % P.O. 
17. The scaffold of claim 1 wherein the scaffold body 
components consist essentially of 40 to 90 wt % BO, 1 to 
25 wt % LiO, and 1 to 40 wt % CaO. 
18. The scaffold of claim 1 wherein the scaffold body 
components consist essentially of 40 to 90 wt % BO, 1 to 
25 wt % NaO, and 1 to 40 wt % CaO. 
19. The scaffold of claim 1 wherein the scaffold body 
components consist essentially of 40 to 90 wt % BO, 0.1 
to 5% CuO, 1 to 25 wt % NaO, 1 to 25 wt % K2O, 1 to 25 
wt % MgO, and 1 to 10 wt % P.O. 
20. The scaffold of claim 1 wherein the scaffold body 
components consist essentially of the fibers and the par 
ticles. 
21. The scaffold of claim 1 wherein the scaffold body 
components comprise the fibers and the solid spheres. 
22. The scaffold of claim 1 wherein the compressive 
strength of the scaffold body is greater than 5 MPa and no 
more than 200 MPa. 
23. The scaffold of claim 22 wherein the compressive 
strength of the scaffold body is between 20 and 200 MPa. 
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